Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

This phase II randomized trial compares the efficacy and safety of Toripalimab combined with three different platinum-based induction chemotherapy regimens, sequentially followed by standard concurrent chemoradiotherapy, for the treatment of locally advanced nasopharyngeal carcinoma (NPC). The study is aimed to pick up the most effective platinum-based induction chemotherapy regimen plus Toripalimab for these patients which provides the most survival benefit.

NCT Number	NCT07362979
Lead Sponsor	Sun Yat-sen University
Conditions	Nasopharyngeal Cancinoma (NPC)
Enrollment	243 participants
Start Date	2026-03-12
Primary Completion	2029-03-12 (estimated)
Study Completion	2031-03-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-17